Recent examples include knockdown of ACLY impairing pancreatic tumor formation [81] and knockdown of FASN blocking tumor development in mTOR-driven liver cancer [82], while pharmacological inhibition of FAS reduced tumor growth in preclinical models of castration-resistant prostate cancer [83]. Here, FAS is linked to neoplasm.